Cediranib-Lynparza Combo Fails to Delay Disease Progression in Relapsed Ovarian Cancer

Cediranib-Lynparza Combo Fails to Delay Disease Progression in Relapsed Ovarian Cancer
A combination of the investigational therapy cediranib and Lynparza (olaparib) fails to delay disease progression in women with platinum-sensitive relapsed ovarian cancer compared with standard platinum-based chemotherapy, findings from a Phase 3 trial show. The results mean that the trial's main goal — progression-free survival — was not met. Researchers at NRG Oncology, who are leading the trial in collaboration with the National Cancer Institute (NCI), are now examining the full data to inform the future of the clinical trial and their ongoing research. The data will be presented at an upcoming medical meeting, according to AstraZeneca and Merck (known as MSD in the United States and Canada), the companies developing and commercializing Lynparza. “Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer,” José Baselga, MD, PhD, executive vice president of oncology research and development at AstraZeneca, said in a
Subscribe or to access all post and page content.